[Translation] A multicenter, open, single-arm, non-randomized Phase I clinical trial: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the pan-FGFR inhibitor SC0011 tablets in patients with advanced malignant solid tumors, and to preliminarily explore the anti-tumor activity of SC0011 tablets
1、评价SC0011 片的安全性和耐受性;
2、确定SC0011 片的最大耐受剂量(MTD)和II 期推荐剂量(RP2D);
3、评价SC0011 片的药代动力学(PK)特征;
4、评价SC0011 片的药效动力学(PD)特征;
5、初步评价SC0011 片的抗肿瘤活性;
6、初步评价在FGFR 基因检测异常受试者中SC0011 片的疗效。
[Translation] 1. Evaluate the safety and tolerability of SC0011 tablets;
2. Determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of SC0011 tablets;
3. Evaluate the pharmacokinetic (PK) characteristics of SC0011 tablets;
4. Evaluate the pharmacodynamic (PD) characteristics of SC0011 tablets;
5. Preliminary evaluation of the anti-tumor activity of SC0011 tablets;
6. Preliminary evaluation of the efficacy of SC0011 tablets in subjects with abnormal FGFR gene detection.